
Agenus’ BOT/BAL Wins AAC Reimbursement in France for Refractory MSS mCRC
France Grants Reimbursed Compassionate Access for Agenus’ Botensilimab plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer In a significant development for patients with advanced colorectal cancer, Agenus Inc. (Nasdaq: AGEN), a biotechnology company at the forefront of immuno-oncology innovation, announced…











